Coalition for Better Health
Independent research for informed health decisions
This month's focus
GLP-1 Receptor Agonists: Separating Evidence from Hype
Our latest position paper examines the clinical trial data behind GLP-1 therapeutics, long-term metabolic outcomes, and what the evidence actually supports for Australian patients.
Read the research →Featured Research
Featured Research
State of Metabolic Health in Australia 2026: Evidence Report
Metabolic health in Australia, 2026: overweight or obesity affects about 67% of adults (roughly 31% obese), 1.3 million live with diabetes, and direct obesity costs run to $11.8 billion. A reform reference.
The Future of Weight Management: Beyond Lifestyle Advice
From lifestyle intervention through bariatric surgery to next-generation pharmacotherapy: an evidence-based look at how obesity treatment research is evolving.
The Obesity Crisis in Australia: What the Evidence Tells Us
Australia faces a serious and worsening obesity crisis. Current prevalence data, the economic burden, and why metabolic science is reshaping research.
Our Mission
CoalitionForBetterHealth.org is an independent platform dedicated to evidence-based health research, metabolic science, and informed healthcare decisions.
Recent Articles
View all →Australia Obesity Statistics 2026: Rates, Trends & Costs
Australia obesity statistics 2026: about two in three adults overweight or obese (roughly a third obese), one in four children affected, $11.8B in costs. State data since 1995.
Menopause Healthcare Reform in Australia: Policy Gaps
The 2024 Senate inquiry into menopause exposed gaps in MHT access, GP training, and PBS listings. What it found, and the reforms still needed to close them.
Sugar Tax Australia: Evidence, Advocacy, and the Debate
International evidence on SSB taxes, Australian advocacy for a sugar levy, industry counterarguments, and the 2024–26 political outlook for reform in Australia.
Telehealth Prescribing of Schedule 4 Peptides: 2026 Brief
Telehealth is permanent in Australian healthcare, but its overlap with Schedule 4 peptide prescribing is under-examined. The framework, gaps, and priorities.
Ultra-Processed Food Policy in Australia: Closing the Gap
Australia has no binding regulation of ultra-processed foods despite evidence linking NOVA Group 4 consumption to metabolic disease. Reform and global lessons.
Vaping Reform in Australia 2026: A Policy Analysis
Australia's prescription-only vaping model, the 2024 pharmacy supply amendments, patchy enforcement, and youth uptake inside the 2026 harm-reduction debate.